P53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 230-235

  Buttitta, F ^a   Marchetti, A ^a   Gadducci, A ^a   Pellegrini, S ^a   Morganti, M ^a   Carnicelli, V ^a   Cosio, S ^a   Gagetti, O ^a   Genazzani, A R ^a   Bevilacqua, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chemoresistance; cis diamminedichloroplatinum II (cisplatin); Immunohistochemistry; Ovarian carcinoma; p53 expression; p53 mutations; Polymerase chain reaction; Single strand conformation polymorphism

Indexed keywords

CISPLATIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; DRUG RESISTANCE; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 8044233696     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.38     Document Type: Article

References (54)

1. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM and Miller D (1990) C-Myc amplification in ovarian cancer. Gynecol Oncol 38: 340-342
2. Barry MA, Behnke CA and Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxin and hyperthermia. Biochem Pharmacol 40: 2353-2362
3. Bauer JJ, Sesterhenn IA, Mostofi KF, Mcleod DG, Srivastava S and Moul JW (1995) p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1: 1295-1300
4. Beahrs OH, Henson DE and Hutter RVP (1988) Manual for Staging of Cancer, 3rd edn. Lippincott: Philadelphia
5. Bergh J, Norberg T, Sjogren S, Lindgren A and Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034
6. Bookman MA and Bast RC (1991) The immunobiology and immunotherapy of ovarian cancer. Semin Oncol 18: 270-291
7. Bosari S, Lee KC, Viale G, Heatley GJ and Coggi G (1992) Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat 421: 291-295
8. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E and Coggi G (1993) p53 accumulation in ovarian carcinomas and its prognostic implication. Human Pathol 24: 1175-1179
9. Buchman L, Chumakov PM, Ninkina NN, Samarina OP and Georgiev GP (1988) A variation in the structure of the protein-coding region of the human p53 gene. Gene 70: 245-252
10. Carson DA and Ribeiro JM (1993) Apoptosis and disease. Lancet 341: 1252-1254
11. Chin K-V, Ueda K, Pastan I, Gottesman MM (1992) Modulation of activity of the promoter of the human MDRI gene by Ras and p53. Science 255: 459-462
12. Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell 2: 275-280
13. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM and Leonard RCF (1992) Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65: 40-44
14. Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, Bernaudin J-F and Riou G (1995) C-erbB2 gene amplification and protein expression in ovarian epithelial tumours: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer (Pred Oncol) 64: 146-151
15. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542
16. Friedlander ML and Dembo AJ (1991) Prognostic factors in ovarian cancer. Semin Oncol 18: 205-212
17. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176
18. Hart WR (1992) Pathology of malignant and borderline (low malignant potential) epithelial tumours of the ovary. In Gynecologic Oncology, Coppleson M (ed) pp. 863-887, Churchill Livingstone: Edinburgh
19. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, SU JQ, Katzmann JA and Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64-69
20. Hickman JA (1992) Apoptosis induced by anticancer drugs. Cancer metastasis Rev 11: 121-139
21. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162
22. Kacinski BM, Mayer AG, King BL, Carter D and Chambers SK (1992) Neu protein overexpression in benign, borderline, and malignant ovarian neoplasm. Gynecol Oncol 44: 245-253
23. Kappes S, Milde-Langosch KM, Kressin P, Passlack B, Dockhorn-Dworniczak B, Rohlke P and Loning T (1995) p53 mutations in ovarian tumours, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 64: 52-59
24. Kerr JFR, Winterford CM and Harmon BV (1994) Apoptosis: its significance in cancer and cancer therapy. Cancer 73: 2013-2026
25. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U and Mueller H (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344: 1647-1648.
26. Kohler MF, Merks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC and Berchuck A (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513-1519
27. Kupryjanczyk J, Thor AD, Beauchamp R, Merrit V, Edgerton SM, Bell DA and Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965
28. Levesque MA, Katsaros D, YU H, Zola P, Sismondi P, Giardina G and Diamandis EP (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327-1338
29. Lowe SE, Ruley HE, Jacks T and Housman DE (1993a) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
30. Lowe SE, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993b) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849
31. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
32. Majno G and Joris I (1995) Apoptosis, oncosis and necrosis. Am J Pathol 146: 3-15
33. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R, Bistocchi M and Squartini F (1993) p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53: 2846-2851
34. Marks JR, Davidoff AM, Kerns BJ, Humprey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC and Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984
35. Mazars R, Pujol P, Maudelonde Y, Jeanteur P and Theillet C (1991) p53 mutations in ovarian cancer: a late event? Oncogene 6: 1685-1690
36. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE and Hites NE (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53: 2128-2132
37. Miyashita T and Reed JC (1993) Bcl2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157
38. Nabeya Y, Loganzo F, Maslak P, Lai L, DE Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP and Albino AP (1995) The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Canter 64: 37-46
39. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H and Tamaya T (1994) Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70: 1191-1197
40. O'Connor PM, Jackman J, Jondle D, Bathia K, Magrath I and Kohn RW (1993) Role of p53 tumour suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53: 4776-4780
41. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M and Yokota J (1991) Frequent allelic losses and mutations of p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176
42. Orita M, Suzuki Y, Sekiya T and Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879
43. Ormerod MG, Orr RM and Peacock JH (1994) The role of apoptosis in cell killing by cisplatin: cytometric study. Br J Cancer 69: 93-100
44. Perez RP, Hamilton TC, Ozols RF and Young RC (1993) Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71: 1571-1580
45. Piver MS, Baker TR, Piedmonte M and Sandecki AM (1991) Epidemiology and etiology of ovarian cancer. Semin Oncol 18: 177-185
46. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
47. Sasano H, Nagura H and Silverberg SG (1992) Immunolocalization of cmyc oncoprotein in mucinous and serous adenocarcinomas of the ovary. Human Pathol 23: 491-495
48. Serov SF, Scully RE, Sobin LH (1973) Histologic typing of ovarian tumours. In International Histological Classification of Tumours. World Health Organization. No. 9. WHO: Geneva
49. Shaw P, Bovey R, Tardy S, Sahly R, Sordat B and Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon tumour-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499
50. Spinardi L, Mazars R and Theillet C (1991) Protocols for an improved detection of point mutations by SSCP. Nucleic Acid Res 19: 4009
51. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T and Van Dyke T (1994) p53 dependent apoptosis suppresses tumour growth and progression in vivo. Cell 78: 703-711
52. Thompson C B (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462
53. Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M and Shimizu T (1992) Ras oncogene product p21 expression and prognosis of human ovarian tumours. Gynecol Oncol 46: 45-50
54. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-350